Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Macrophage global metabolomics identifies cholestenone as host/pathogen cometabolite present in human Mycobacterium tuberculosis infection
Pallavi Chandra, Héloise Coullon, Mansi Agarwal, Charles W. Goss, Jennifer A. Philips
Pallavi Chandra, Héloise Coullon, Mansi Agarwal, Charles W. Goss, Jennifer A. Philips
View: Text | PDF
Research Article Infectious disease Microbiology

Macrophage global metabolomics identifies cholestenone as host/pathogen cometabolite present in human Mycobacterium tuberculosis infection

  • Text
  • PDF
Abstract

Mycobacterium tuberculosis (M. tuberculosis) causes an enormous burden of disease worldwide. As a central aspect of its pathogenesis, M. tuberculosis grows in macrophages, and host and microbe influence each other’s metabolism. To define the metabolic impact of M. tuberculosis infection, we performed global metabolic profiling of M. tuberculosis–infected macrophages. M. tuberculosis induced metabolic hallmarks of inflammatory macrophages and a prominent signature of cholesterol metabolism. We found that infected macrophages accumulate cholestenone, a mycobacterial-derived, oxidized derivative of cholesterol. We demonstrated that the accumulation of cholestenone in infected macrophages depended on the M. tuberculosis enzyme 3β-hydroxysteroid dehydrogenase (3β-Hsd) and correlated with pathogen burden. Because cholestenone is not a substantial human metabolite, we hypothesized it might be diagnostic of M. tuberculosis infection in clinical samples. Indeed, in 2 geographically distinct cohorts, sputum cholestenone levels distinguished subjects with tuberculosis (TB) from TB-negative controls who presented with TB-like symptoms. We also found country-specific detection of cholestenone in plasma samples from M. tuberculosis–infected subjects. While cholestenone was previously thought to be an intermediate required for cholesterol degradation by M. tuberculosis, we found that M. tuberculosis can utilize cholesterol for growth without making cholestenone. Thus, the accumulation of cholestenone in clinical samples suggests it has an alternative role in pathogenesis and could be a clinically useful biomarker of TB infection.

Authors

Pallavi Chandra, Héloise Coullon, Mansi Agarwal, Charles W. Goss, Jennifer A. Philips

×

Figure 3

Macrophage cholestenone levels correlate with M. tuberculosis burden and duration of infection.

Options: View larger image (or click on image) Download as PowerPoint
Macrophage cholestenone levels correlate with M. tuberculosis burden and...
(A) Chemical structures of cholesterol and cholestenone showing A–D rings (red text). The 3-hydroxyl group of cholesterol is dehydrogenated to a keto moiety in the A ring in cholestenone (highlighted in green). (B) Cholestenone was quantified from BMDMs infected with M. tuberculosis at MOI 1, 5, and 10, at 3, 24, 72, and 120 hpi. Uninfected (UI) cells or those infected with heat-killed M. tuberculosis (HK) were used as controls. Plot shows average of 2 independent experiments.*P = 0.03, **P = 0.007 for 120 hours, calculated using Mann-Whitney test. (C) Cholestenone levels in PMA-differentiated THP-1 macrophages that were uninfected or M. tuberculosis–infected at MOI 10, 72 hpi. (D) Growth of M. tuberculosis was compared in minimal medium supplemented with either a vehicle control, 100 μg/mL 25-HC, or 100 μg/mL cholesterol. Plot shows values from 1 experiment representative of 3 independent experiments. (E) Cholestenone abundance and (F) corresponding M. tuberculosis CFU in IFN-γ–activated and naive BMDMs that were uninfected or M. tuberculosis–infected at MOI 10 at the indicated time points. (G and H) The direct effect of cholestenone on M. tuberculosis growth was assessed in culture medium using absorbance measurements (G) and CFU (H). (C, E, and F) Plots show mean ± SEM from at least 3 independent experiments. **P = 0.007, ****P < 0.0001 calculated using Student’s t test (C), and 1-way ANOVA with Tukey’s multiple comparisons test (E and F). (G and H) Plots show average of 2 independent experiments. Also see Supplemental Figure 6. (C and E) The dotted line on the y axis represents the limit of detection accuracy as determined by the standard curve. For all macrophage experiments, one million cells were infected and the samples were extracted in 500 μL 80 % methanol solution containing 0.1 μg internal standard. The methods used for calculating cholestenone concentrations are detailed in the Supplemental Material.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts